Video

LCZ696 Could Set New 'Gold Standard' for Heart Failure Treatment

Author(s):

With heart failure increasing in prevalence as the US population ages, early detection and more effective treatments are important. Now, data from clinical studies show that treatment with the experimental angiotensin receptor neprilysin inhibitor LCZ696 can significantly reduce patients' risk of sudden death and hospitalization.

With heart failure increasing in prevalence as the US population ages, early detection and more effective treatments are important. Now, data from clinical studies show that treatment with the experimental angiotensin receptor neprilysin inhibitor LCZ696 can significantly reduce patients' risk of sudden death and hospitalization.

Scott Solomon, MD, discussed the progress made in studies involving LCZ696 during an interview at the 2014 American Heart Association Scientific Sessions in Chicago.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Experts' Perspectives: Top Stories in Cardiology for 2024
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
© 2025 MJH Life Sciences

All rights reserved.